Why is Alivus Life falling/rising?

As of 19-Aug, Alivus Life Sciences Ltd is experiencing a decline in its stock price, currently at 958.60, reflecting a decrease of 1.4 points or 0.15%. The stock's performance today is in line with its sector, although it is trading higher than its 5-day moving averages but lower than the 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a notable drop in investor participation, with delivery volume falling by 30.16% against the 5-day average. Over the past month, the stock has seen a significant decline of 9.24%, while its year-to-date performance shows a decrease of 3.07%. Despite a high management efficiency indicated by a return on equity (ROE) of 25.32% and a low debt-to-equity ratio, the stock is trading at a premium compared to its peers, which may be contributing to its recent price movement.
In the broader market context, the Sensex has outperformed Alivus Life, with a 1-week return of 1.76% compared to the stock's slight gain of 0.05%. This underperformance is further highlighted by the stock's negative returns over the past month and year, contrasting with the Sensex's positive returns of 4.49% and 1.52%, respectively. The company's long-term growth prospects appear poor, with net sales and operating profit growth rates of only 4.49% and 2.26% over the last five years. These factors, combined with flat results reported in June, suggest that the stock's recent decline may be influenced by both its relative performance against the benchmark and concerns regarding its growth potential.